Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Nov 1;11(1):2141978.
doi: 10.1080/2162402X.2022.2141978. eCollection 2022.

Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy

Xinxin Song  1 , Zhuan Zhou  1 , Rui Kang  1 , Daolin Tang  1
Affiliations
Comment

Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy

Xinxin Song et al. Oncoimmunology. .

Abstract

The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a link between T cells and tumor cells to selectively eliminate G12Ci-resistant cells.

Keywords: KRAS-G12C; bispecific T cell engagers.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest or financial interests.

Figures

Figure 1.
Figure 1.
Bispecific T cell engagers designed to clear KRAS-G12C inhibitor-resistant cancer cells. G12C inhibitors (G12Ci) produce covalently modified peptides that undergo antigen processing, proteasomal degradation, peptide transport, presentation, and ultimately G12Ci-peptide-MHCI recognized by cytotoxic T cells. The top of the figure summarizes the bispecific T-cell engagers development strategies of two independent groups.
See this image and copyright information in PMC

Comment on

References

    1. Veluswamy R, Mack PC, Houldsworth J, Elkhouly E, Hirsch FR.. KRAS G12C-mutant non-small cell lung cancer: biology, developmental therapeutics, and molecular testing. J Mol Diagn. 2021;23:507–3. doi:10.1016/j.jmoldx.2021.02.002. - DOI - PubMed
    1. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548–551. doi:10.1038/nature12796. - DOI - PMC - PubMed
    1. Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, et al. Adagrasib in Non–small-cell lung cancer harboring a KRAS G12C mutation. N Engl J Med. 2022;387:120–131. doi:10.1056/NEJMoa2204619. - DOI - PubMed
    1. Tang D, Kroemer G, Kang R. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges. Mol Cancer. 2021;20:128. doi:10.1186/s12943-021-01422-7. - DOI - PMC - PubMed
    1. Zhang Z, Rohweder PJ, Ongpipattanakul C, Basu K, Bohn MF, Dugan EJ, Steri V, Hann B, Shokat KM, Craik CS. A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy. Cancer Cell. 2022;40:1060–9.e7. doi:10.1016/j.ccell.2022.07.005. - DOI - PMC - PubMed

Publication types

Substances